StockData
Upstream Bio, Inc. logo

Upstream Bio, Inc. (UPB) stock

UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$2.08−0.02 (-0.95%)

Close on Nov 18, 2026Market cap $113.92MP/E –Yield –

Upstream Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Upstream Bio's operating income for the twelve months ending Sep 30, 2026 was -$175.53M. For fiscal 2025 it was -$160.36M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$160.36M–
FY2024Dec 31, 2024-$77.76M–
FY2023Dec 31, 2023-$40.11M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$43.38M–
Q2 FY2026Jun 30, 2026-$42.37M–
Q1 FY2026Mar 31, 2026-$43.62M–
Q4 FY2025Dec 31, 2025-$46.17M–
Q3 FY2025Sep 30, 2025-$37.83M–
Q2 FY2025Jun 30, 2025-$44.35M–
Q1 FY2025Mar 31, 2025-$32.01M–
Q4 FY2024Dec 31, 2024-$26.32M–
Q3 FY2024Sep 30, 2024-$18.89M–
Q2 FY2024Jun 30, 2024-$17.54M–
Q1 FY2024Mar 31, 2024-$15.01M–
Q4 FY2023Dec 31, 2023-$14.33M–
Q3 FY2023Sep 30, 2023-$9.39M–

More Upstream Bio figures

See a number that looks wrong?